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Introduction
An arginine to lysine substitution in the coding region of the β-chain of fibrinogen, BβArg448Lys, is a relatively common polymorphism, of which the Lys448 allele has a frequency of 15-20% in Caucasians 1, 2 . A previous study has shown an association between BβArg448Lys polymorphism and the severity of coronary artery disease as assessed by angiography 3 , with an increased frequency of the Lys448 allele in patients with triple vessel disease compared with patients having single vessel or two vessel disease. The polymorphism has also been implicated in predisposition to stroke in female patients, an effect that was independent of fibrinogen levels, suggesting a functional role for this polymorphism 2 . We have previously shown that genetic factors contribute to the ultrastructure of the fibrin clot and that more than a third of the variation in fibrin structure is determined by genes 4 . Clot structure has a role in determining the predisposition to atherothrombotic disease as clots composed of tightly packed, thin fibres and small pores are associated with increased risk of cardiovascular disease 5 . Furthermore, changes in clot structure have been reported to affect interactions with endothelial cells and fibroblasts, whereby dense fibrin structures with small pores impaired reorganization of these cells into microtubules 6 , implicating effects on angiogenesis, wound healing and atherosclerosis 7 .
Fibrin clot formation initiates with cleavage of fibrinopeptide (Fp)A from the fibrinogen Aα-chain by thrombin, exposing a binding site in the E-region that interacts with a complementary binding site on the γ -chain in the D-region, allowing formation of protofibrils.
Thrombin cleavage of fibrinopeptide (Fp)B from the Bβ-chain occurs at a slower rate and is thought to also expose a binding site, this time for a complementary region on the β-chain, again located in the D-region. The precise function of this latter interaction is still a matter for debate. Interactions of the β-chain have been proposed to play a role in conformational changes in α-chain C-terminal region and lateral aggregation of fibrin protofibrils, which
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From determines fibre thickness and final ultrastructure of the clot 8, 9 . The location of the BβArg448Lys polymorphism is relatively close to three areas of interest: the proposed β-chain polymerization site, a β-chain interaction site for the C-terminal region of the α-chain, and a β-chain calcium binding site. We postulate that due to this location, BβArg448Lys may have a role in modulating fibrin polymerization, potentially affecting the final ultrastructure of the clot. Previous work on the effect of this polymorphism on fibrin structure has, however, led to conflicting results. We previously observed that BβLys448 associated with a tighter clot structure compared to BβArg448 in plasma samples, whilst others failed to detect such differences 10, 11 . This discrepancy may have been caused by the use of plasma samples and plasma purified fibrinogen respectively in these studies. Non-inherited post-translational modifications which occur during synthesis and circulation in plasma could obscure the functional effect of a fibrinogen polymorphism in plasma samples 12 . Also, plasma purified samples may contain other genetic variations such as the AαThr312Ala polymorphism, which has been shown to alter fibrin function 13 , potentially resulting in inconsistent or contradictory data.
The aim of the current work was to investigate the role of BβArg448Lys on fibrin clot structure and function using recombinant BβArg448 and BβLys448 variants to reduce to a minimum any other potential heterogeneity (genetic or post-translational), which may be associated with plasma purified fibrinogen. We found that BβArg448Lys polymorphism is associated with significant changes in fibrin clot structure and rigidity which is in agreement with a model that supports a role for the C-terminal region of the fibrinogen β-chain in fibrin formation and structure.
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Methods

Vector construction and expression of recombinant fibrinogen
The expression vector pMLP-β, which contains the entire fibrinogen β-chain cDNA, was a gift from Prof. Susan Lord (University of North Carolina at Chapel Hill, USA) and has been described elsewhere 14, 15 . Codon 448 was changed from Arg (AGG) to Lys (AAG) using the QuickChange site directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The following primers (Invitrogen, Poole, UK) were used (mutated base underlined):
Forward: 5' GGAAGGGGTCATGGTACTCAATGAAGAAGATGAGTATG 3'
Reverse: 5' CATACTCATCTTCTTCATTGAGTACCATGACCCCTTCC 3'
Primers were designed according to manufacturer's guidelines and were PAGE-purified. The mutation was confirmed by sequencing using an ABI PRISM312 automated sequencer (Applied Biosystems, Warrington, UK). Chinese Hamster Ovary (CHO) cells expressing the human Aα and γ fibrinogen chains were co-transfected with the Lys448 β-chain vector and a plasmid containing a selection gene, pMSV his 16 . Individual clones selected for high fibrinogen expression were grown in serum free medium in roller bottles. Harvested medium was supplemented with 100 mmol/L phenylmethylsulfonyl fluoride and stored at -20ºC until purification. Wild type (BβArg448) fibrinogen was obtained from CHO cells capable of expressing all three chains as previously described 14 . Both CHO cell clones were donated by Prof. Susan Lord. Fibrinogen was precipitated from culture medium by ammonium sulphate and further purified by affinity chromatography using the IF-1 antibody 17 . Integrity of the samples was analysed by SDS-PAGE. Fibrinogen concentration was determined at 280nm using the extinction coefficient ε 280 =1.506 and adjusted to a dilution of 1 mg/ml. To determine clottability, subsamples (100 µ l) from each preparation were clotted by adding 0.5 U/ml thrombin and 2.5 mmol/L CaCl 2 (final concentration). Samples were incubated for 2h at ambient temperature, and clotted fibrin was removed by centrifugation at 13000 × g for 10 
Preparation of Factor XIII
A plasma-based concentrate of FXIII, used clinically for the treatment of patients with FXIII deficiency (Fibrogammin®P , ZLBBehring, Sussex, UK), was separated from contaminating albumin and glucose using gel filtration on sepharose 6B (40X2.5 cm).
Clot permeation experiments
Recombinant fibrinogen at 1.3 µmol/L was incubated with 0.5 U/ml human thrombin (Sigma, St Louis, MO, USA) and 2.5 mmol/L CaCl 2 in open tubes for 2 h at room temperature in a wet chamber to allow for full clot formation. Permeation of 50 mmol/L Tris, 100 mmol/L NaCl, pH 7.4 was measured as described previously, with a pressure drop of 2 cm, and the Darcy constant K s was subsequently calculated 18, 19 . Permeation experiments were also conducted by adding 3 volumes of recombinant fibrinogen variants at 1.3 µmol/L to one volume of plasma immunodepleted of fibrinogen (Diagen Diagnostic Reagents, Oxon).
Fibrinogen-depleted plasma was prepared by passing a pool of normal control plasma over immobilized monoclonal anti-fibrinogen antibody. The resulting plasma is depleted to less than 0.5% of fibrinogen, without significantly affecting levels of other clotting factors. In the preparation used, plasma levels of FII, FV, FVII, FIX and FX were 89-90% the levels detected before fibrinogen depletion. 
Thrombin-catalyzed fibrin polymerization
Fibrinogen variants, at a final concentration of 1.3 µmol/L, were mixed with 0.5 U/ml thrombin and 2.5 mmol/L calcium chloride in 100 mmol/L NaCl, 50 mmol/L Tris, pH 7.4 at ambient temperature in a 96 well plate. Four replicates were performed for each variant.
Increase in turbidity was continually monitored every 12 seconds on a FLX-800 multiwell plate reader (Biotek Instruments Inc, Winooski, VT, USA) over a period of 60 minutes.
Recombinant fibrinogen variants were also added to fibrinogen-depleted plasma as described above, and turbidity analysis was repeated. 
Scanning electron microscopy of fibrin
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Elastic properties of clots made from recombinant fibrinogen
Stiffness of clots made from recombinant fibrinogen was measured by magnetic tweezers, which operate by exerting a force to a micron-scale magnetic particle using an external magnetic field gradient. A custom built magnetic tweezer device was used to exert 100 pN force pulses of 5 secs duration every 30 secs for either 60 or 180 minutes. This technique has been previously applied to actin networks 20 , where the particle is free to flow through the sample. In the case of fibrin, however, the particle is restricted by the fibrous network of the fibrin sample. The octopolar design of Huang et al 21 was used, allowing 3D control over the particle, although particle movement was restricted to 1D in this study. The tweezers were used in conjunction with an Olympus IX71 optical microscope incorporating x40 ultra-long working distance objective. Force calibration was achieved by applying Stokes' law to particles held in 100% glycerol. All particle tracking, electromagnet control, and image analysis was performed in real-time, and achieved using custom written software (Labview 7.1).
Clots were made from 1.3 µmol/L recombinant fibrinogen Arg448 or Lys448 as described above in the presence of 4.5 µ m superparamagnetic particles (Dynal, Oslo). The particles, dispersed in a small amount of distilled water, were first added to the fibrinogen, which was then mixed with 0.5 U/ml thrombin and 2.5 mmol/L calcium. The resulting mix was quickly placed into a thin glass capillary tube. As the fibrin polymerisation took place, the magnetic particles were caught in the resulting network. A suitable particle was then found, away from the capillary walls, and the force pulses applied. Experiments with both recombinant variants were repeated in the presence of FXIII (0.068 µmol/L final concentration). For each sample, the time development of the clot stiffness was measured for up to 180 minutes. After this period, several other particles were displaced with force pulses in order to test the elasticity of different sample regions.
Macroscopic lysis of recombinant fibrin clots
Macroscopic lysis velocity of recombinant fibrin clots was assessed directly after completion of polymerisation at 60 minutes in the microtiter plates used for turbidity analysis. All wells were overlaid with 100 µ l of a mixture of 10 nmol/L tissue plasminogen activator (Technoclone, Vienna, Austria) and 0.05 mg/ml Glu-plasminogen (Calbiochem). Changes in turbidity were monitored every 12 seconds for 60 minutes, as above. Lysis experiments were also conducted by adding the recombinant variants to plasma immunodepleted of fibrinogen as described above. One volume of fibrinogen-depleted plasma was added to 3 volumes of recombinant fibrinogen at 1.3 µmol/L and lysis experiments were conducted as above for 2 hours, and these were further extended to 7 hours due to incomplete lysis of the clot at 2 hours.
Microscopic lysis of recombinant fibrin clots and fibrin structure by confocal microscopy
Real time microscopic lysis was determined using laser confocal scanning microscopy as previously detailed by Collet et al. 22 . Recombinant fibrinogen was used at 1.3 µmol/L with calcium at 5 mM and thrombin at 1U/ml. After clot formation, plasminogen activator (tPA) and plasminogen were added at 10 nmol/ml and 0.1 mg/ml final concentrations respectively to the border of the clot. Fibrinolysis rates were observed and recorded every 2 minutes for each of the fibrinogen variants using Leica TCS SP-2 laser scanning confocal equipment on an inverted DM IRE 2 microscope with 63x water immersion objective, with characterization of at least 4 areas of 240 x 240 x 40 µm were characterized per sample.
Molecular modeling
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Four models in total were constructed based on atomic coordinates from the x-ray crystallographic structure of the fibrinogen D-fragment 23, 24 . The Arg448 I model had polar hydrogen atoms built on using the HBUILD facility in CHARMM 25 .
A first Lys variant model (Lys I) was prepared from Arg I by changing the side-chain of BβArg448 into that of a lysine with the same conformation. A second Lys variant model (Lys II) was prepared from the first by positioning the BβLys448 side-chain in a low energy conformation as determined by a rigid body mapping of the side-chain dihedral space. The three models were subjected to severe energy minimization (one phase of restrained minimization and one of unrestrained) until the potential energy gradient for the current minimization step was less than 10 -5 . The minimized models were subjected to Normal Modes Analysis using DIMB diagonalisation as implemented in CHARMM 26 . The lowest frequency modes (100 in all) were computed for each model system.
A further Arg variant model was constructed (Arg II) from the atomic coordinates of the fibrinogen D-fragment 23, 24 with polar hydrogens added. The system was left unrestrained and then subjected to 10ps of equilibration at 100K followed by 10ps of production dynamics at 100K. This structure (RMS deviation in atomic coordinates=2.7Å) was subjected to the same protocol of Normal Modes Analysis. This second wild type model was prepared to eliminate the possibility that the hydrogen bonding between BβArg448 and BβGlu315 is an artifact of some fortuitous positioning of the Arginine side chain in the crystal structure.
For each model, 100ps of unrestrained Molecular Dynamics was then performed. This allowed exploration of the shifts in hydrogen bonding and side chain conformations with time. The starting model for each simulation was a partially minimized model corresponding to the restrained model from the above normal modes analyses. The dynamics was performed using the Verlet algorithm molecular dynamics as implemented in CHARMM and the SHAKE algorithm on hydrogen bearing bonds 27 . The systems were subjected to 20ps of equilibration at 300K followed by 100ps of production dynamics at 300K. Analysis was performed using CHARMM and the graphical visualization tool SQUID 28 .
Results
Expression of recombinant Bβ448 fibrinogen variants
We synthesized both Bβ448 fibrinogen with arginine and lysine at codon 448 in the Bβ chain to mimic the naturally occurring BβArgLys448 and BβArg448 variants of fibrinogen. The entire cDNA from both variants was sequenced and the only difference was Arg to Lys substitution at position 448. SDS-PAGE under reducing conditions showed that both recombinant variants contained the expected bands representing the Aα, Bβ, and γ chains of fibrinogen and that the mutation from Arg to Lys did not affect the migration of the Bβ chain (Fig.1A) . Clottability of samples was 97 ± 1.1% for Arg448 and 95.4 ± 1.2% for Lys448.
Permeability of fibrin clots formed from recombinant fibrinogens
The Darcy constant (Ks) is a direct measure of the clot surface area available for flow and gives information on the size of pores within the fibrin gel. For
Thrombin-catalyzed fibrin polymerization of recombinant fibrinogens
We observed pronounced differences in the polymerization rate between both variants.
Curves that represent average values of four experiments for each recombinant variant (Fig.   1B) showed a lower rate of fibre aggregation (reduced slope of the curve) and smaller fibre size (final maximum absorbency at 350 nm) for Lys448 when compared with Arg448 fibrin.
The difference in final turbidity agrees with the magnitude of the difference observed in permeation. A similar pattern was observed when recombinant fibrinogen variants were added to fibrinogen-depleted plasma (Fig. 1C) .
Ultrastructure of fibrin clots formed from recombinant fibrinogens
Clots prepared from recombinant Lys448 fibrinogen showed a dense and thin fibrin network with small interstitial pores by both scanning electron microscopy and laser scanning confocal microscopy ( Fig. 2) . In contrast, clots made using the Arg448 variant were characterized by fibrin fibres with larger diameter and bigger interstitial pores. In Lys448 fibrin clots, the average fibre diameter was 80 ± 22 nm compared to 126 ± 35 nm in Arg448 clots (p<0.05) as measured on the scanning electron micrographs.
Elastic properties of the fibrin clot formed from recombinant fibrinogen variants
The compliance J of the samples was measured using
Where r = radius of particle, x = displacement of particle, F = force.
The elastic modulus was then calculated using equation below, which is obeyed for a purely elastic material.
At the low forces and low pulse durations used in this work, the viscous component of the fibrin fibres was negligible.
G' was measured throughout clot formation from 5 to 45 minutes in both variants in the absence and presence of FXIII. Experiments were repeated at least 3 times and mean values are presented in Fig. 3 . In clots formed from fibrinogen Arg448, G' reached a plateau in less than 30 minutes. In contrast, clot stiffness of the Lys448 clots continued to increase after 30 minutes and G' was almost 3 fold higher than Arg448 variant (p<0.001). In the presence of FXIII, clot stiffness increased markedly, manifested by more than doubling of G' in both variants. We also measured G' in clots formed in the presence of FXIII over an extended period of time. In the Arg448 variant, G' reached plateau at approximately one hour, whereas in the Lys448 variant, G' was still increasing after 3 hours (data not shown).
Macroscopic and microscopic lysis of clots formed from recombinant fibrinogen
Macroscopic analysis of fibrinolysis by turbidity was largely similar in the two variants in four repeat experiments (p>0.1; Fig. 4 ). Time to 50% lysis took 24 minutes in each variant.
Real time lysis rates were also observed using laser scanning confocal microscopy and experiments were repeated on 8 and 12 occasions with the Arg448 and Lys448 respectively.
The mean lysis speed (±SEM) of clots formed from Arg448 variant was 13.6 µm/min (±2.1), and 14.3 µm/min (±2.5) for clots formed from the Lys448 variant (p>0.1; data not shown). 
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In contrast, there was a significant difference between the two variants when analysis was repeated after adding the recombinant proteins to fibrinogen-depleted plasma. As expected, lysis time increased for both variants in plasma but this increase was significantly more pronounced for the Lys448 compared with Arg448 variant (p<0.001). Results are summarised in Fig. 4 and presented as the mean of 6 experiments (± SEM). Time to 50% lysis for Arg448 in plasma was 64 minutes, whereas this was more than double at 156 minutes for Lys448, indicating a significant effect of this polymorphism on fibrinolysis rate in the plasma milieu.
Molecular modeling
Inspection of the vibrational modes computed for the two BβArg448 and the two BβLys448 models showed that there were no discernable differences between the Arg 448 and the Lys 448 variants in the rigid body motions of the αC domain relative to the B domain.
Examination of the hydrogen bonding patterns around the mutation site revealed differences between the models for the two Bβ448 variants (Fig. 5) . The hydrogen bond between Bβ448 NH1 and BβGlu315 OE2 lasted 94% and 73% of the lifetime of simulations Arg I and Arg II respectively. The corresponding hydrogen bond from BβLys448 NZ to BβGlu315 OE2 could not occur at all during the either of the Lys448 simulations. The mean distances between these atoms during the simulations were 2.9Å and 3.0Å (Arg448 simulation I and II respectively), 6 .8Å and 6.5Å (Lys448 simulation I and II respectively). It is possible that the 'lost' hydrogen bonding from BβLys448 could be compensated for by hydrogen bonding to solvent molecules (not included explicitly in our simulations) as the Lys 448 side chain is oriented more towards the exterior of the protein than is Arg 448 and thus the mutation would not necessarily destabilize the protein molecule. Most crucially, the interaction between BβAsp398 and AαLys157 could also be weakened by the variation at Bβ448. This interaction is thought to be responsible for anchoring the Cterminal region of the beta chain to the alpha chain in the coiled-coil in wild type fibrinogen 24 . The interaction survives for 99% and 97% of the simulation time for the two Arg448 simulations (Arg I and II). In the Lys448 simulations ( Lys I and II) these survival times have been reduced to 15% (NZ A157-OD1 B398) and 41%(NZ A157-OD2 B398) in simulation Lys I and a mere 1%(NZ A157-OD2 B398) in simulation Lys II, with the hydrogen bond NZ A157-OD1 B398 not occurring in this simulation. Although the simulations failed to show hydrogen bonds between BβArg448 and BβGlu397 or BβAsp398, these residues appeared more mobile in Lys448, suggesting that this variant enhances the flexibility of the molecule in this region by mechanisms that are unclear.
Discussion
We found that a common mutation in the fibrinogen β-chain, Arg448Lys, influenced fibrin structure, clot rigidity, fibrinolysis rate and conformation of the D-region of fibrinogen by molecular modeling. These effects were observed with variants produced by recombinant technology, strongly suggesting that the amino acid substitution itself is responsible for the observed changes.
The formation of thinner fibrin fibres with BβArgLys448 suggests that lateral aggregation is affected in this variant, which may be caused by several mechanisms. The substitution of Arg with Lys may induce conformational changes in the Bβ-chain of fibrinogen, a hypothesis supported by previous work showing that a similar substitution in other proteins can induce significant changes in the molecule 29, 30 . In support of this hypothesis, dynamic molecular modeling based on crystallographic coordinates suggest that the Arg to Lys substitution could result in the weakening or loss of 3 hydrogen bonds in an area of the fibrinogen molecule close to the proposed b site that may be involved in lateral aggregation 31 . The abolition of a hydrogen bond between Bβ448 and Bβ315 secondary to Arginine to Lysine substitution could potentially destabilise Bβ398 and Aα157 interaction in the coiled coil 32 . This may result in altered αC domain conformation, affecting in the process lateral aggregation 33 . Furthermore, the apparent increased mobility of residues BβGlu397 and BβAsp398 in Lys448, which have been shown to play a critical role in B-b interaction, may influence fibrin polymerization of this variant 34 . Together, these conformational changes as indicated by molecular modeling could result in defective B:b or αC domain interactions and consequently impair lateral aggregation.
We demonstrated an increase in clot stiffness in the Lys448 variant even before crosslinking by FXIII. An association between tight clot structure and increased stiffness has been [35] [36] [37] , which is in agreement with our findings.
Differences in clot stiffness between the two variants were even more pronounced after the addition of FXIII. In both variants, clot stiffness greatly increased in the presence of FXIII.
However, stiffness in crosslinked Arg448 fibrin reached a plateau in less than 30 minutes, whereas that of crosslinked Lys448 fibrin was still increasing after 3 hours, with a G' value almost 3 fold higher compared with Arg448 fibrin. The reason for the continued increase in stiffness of the Lys448 variant (even without FXIII) is unclear and it may be related to continued structural re-arrangement of the fibrin fibrils with this variant 38 , which does not occur, or is less pronounced, with Arg448.
Out of the plasma environment we found lysis rates of the two variants to be comparable, despite the observed alterations in clot structure. In contrast, a major difference in fibrinolysis was detected when the recombinant proteins were added to fibrinogen-depleted plasma. This suggests that clot structure/rigidity per se do not necessarily affect fibrinolysis rates, and that the interaction between clot structure and fibrinolysis is more complex than previously thought, especially in the presence of other plasma proteins 22, 39, 40 . The similar lysis rates of clots formed from the two variants could be explained by relatively quicker lysis of individual thin fibres "compensating" for the increased number of fibres in the Lys448 variant 22 .
However, when in plasma, different proteins are cross-linked or attached to the final clot (hence the prolongation in fibrinolysis rates in plasma with both variants) and due to the more compact structure of Lys448, it is possible that the composition of these fibrin associated proteins is different quantitatively or qualitatively, thereby compromising the fibrinolytic process. Differences in the incorporation of α2-plasmin inhibitor into the clot, plasminogen binding or conversion rates of plasminogen to plasmin could play a role and therefore investigating the association between clot structure, protein interactions and lysis rate in relation to BβArg448Lys remains an area for future research. Our data suggest that Arg448Lys polymorphism influences fibrinolysis through yet unidentified plasma factors, and clot structure may play an indirect role.
The association between a compact clot structure and premature coronary artery disease 40, 41 together with our findings of a significant effect of fibrinogen Arg448Lys polymorphism on clot structure/fibrinolysis, may help to explain the presence of more extensive coronary artery disease in individuals with the Lys448 variant 
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